The Biopharmaceutical Industry in 2017: Highlights by Therapeutic Area

For the biopharmaceutical industry, 2017 was marked by noteworthy innovation as well as disappointments across therapy areas, set against a backdrop of remarkable advances in technology in healthcare and the growing presence of biosimilars. Each of the major therapeutic areas — oncology, immunology, neurology, cardiovascular diseases, metabolic disorders, infectious diseases, and ophthalmology — saw a range of clinical breakthroughs, setbacks in R&D, and advances in digital health. Within oncology, immunology, and ophthalmology, the late-stage development and launches of biosimilars continued to gradually reshape the competitive landscape in 2017.

Scope

GlobalData’s The Biopharmaceutical Industry in 2017: Highlights by Therapeutic Area provides an insight-rich overview of the key events and trends that shaped the industry during 2017. Within each of the major therapeutic areas covered, GlobalData’s analysts have identified the most impactful happenings during 2017 — such as product launches and label expansions, losses of patent protection and market exclusivity, and key clinical trial data readouts — and provided expert insight on the implications of each event.

Reasons to buy

Gain insight into the key trends that shaped the biopharmaceutical industry in 2017 by therapeutic area.

Understand major 2017 events across drug development, disease competitive landscapes, and digital health.

Identify the top 20 companies and the top 10 drugs in each therapeutic area by 2017 revenue.

Companies mentioned

The top 20 companies in 2017 in each of the following major therapeutic areas are mentioned: oncology, immunology, neurology, cardiovascular diseases, metabolic disorders, infectious diseases, and ophthalmology. In addition, key players in the digital health space who made progress in 2017 are included.

Table of Contents

Introduction

Oncology

Top Players in Oncology in 2017

CAR-T Approvals Fuel Optimism in Difficult-to-Treat Diseases, But Feasibility Questions Remain

Checkpoint Inhibitors Continued to Demonstrate Clinical Benefit Across a Wide Range of Tumors

As CPIs Gather More Market Approvals, Combination Regimens Will Be the Main Strategy to Differentiate their Clinical Benefit

PARP Inhibitors Market Sees Surge in Activity in 2017

PARP Inhibitors Landscape Undergoes Momentous Changes

Approval of Cancer Therapeutics a Tipping Point in the Oncology Biosimilar Space

Digital Health Advances in Oncology in 2017 Made Significant Progress in Various Areas of Clinical Treatment

Immunology

Top Players in Immunology in 2017

Increasing Development of JAK Inhibitors Creates Welcome Competition Among Oral Small Molecules

Interleukin Inhibitors Have the Potential to Become First-Line Therapies Across Autoimmune Diseases

Biosimilars Steal Increasing Market Share in Immunology Indications, but Face Challenges in the US Before Reaching Peak Sales

Digital Advances Provide Promising Solutions for Chronic Disease Management

Neurology

Top Players in Neurology in 2017

Two Failures Within the 5-HT6 Receptor Antagonist Class Means the Options for Alzheimer’s Disease Are Waning

More Headwind for the Adenosine A2a Receptor Antagonist Drug Class

The anti-CD20 mAb Drug Class is Anticipated to Reshape the Current Treatment Landscape in Multiple Sclerosis

Digital Health Highlights in Neurology in 2017

Cardiovascular and Metabolic Disorders

Top Players in Cardiovascular Diseases in 2017

Top Players in Metabolic Disorders in 2017

PCSK9 Inhibitors Showed Slow But Steady Growth in Dyslipidemia Market

GLP-1 Receptor Agonist and SGLT-2 Inhibitor Influx for Type 2 Diabetes Continues

Antithrombotics are the Clear Leaders in Sales Among Cardiovascular Drugs

Digital Health Breaks Barriers in the Cardiovascular and Metabolic Space

Infectious Diseases

Top Players in Infectious Diseases in 2017

Vaccines – 2017 Featured Several Notable Approvals and Setbacks

Antibiotics – Small Pharma Steals the Spotlight in 2017

2017 Developments in Digital Health in Infectious Diseases

Ophthalmology

Top Players in Ophthalmology in 2017

Top Trends in Ophthalmology

The Ophthalmology Biosimilars Market Is Still In Its Infancy

Digital Health Highlights in Ophthalmology in 2017

Appendix

Contributors

About GlobalData

Contact Us

Disclaimer

List of Tables

Table 1: 2017 Highlights in Biopharmaceutical R&D Included High-Profile Successes and Failures

Table 2: Digital Advances Provide Promising Solutions for Chronic Disease Management

Table 3: Two Failures Within the 5-HT6 Receptor Antagonist Class Means the Options for Alzheimer’s Disease Are Waning

Table 4: More Headwind for the Adenosine A2a Receptor Antagonist Drug Class

Table 5: Antibiotics – Small Pharma Steals the Spotlight in 2017

Table 6: Trends in Ophthalmology

List of Figures

Figure 1: Top 10 Companies in Oncology

Figure 2: Top 20 Drugs in Oncology

Figure 3: Key Events in the CAR-T Space in 2017

Figure 4: Checkpoint Immunotherapy Approvals in 2017 and Projected Sales of CPIs in Oncology ($B)

Figure 5: Key Events for Checkpoint Inhibitors in 2017 and Comparison of Ongoing Trials of CPIs in Oncology

Figure 6: Key Events in PARP inhibitors in 2017

Figure 7: Key Events in the Oncology Biosimilar Landscape in 2017

Figure 8: Current and Future Directions in the Oncology Biosimilar Space

Figure 9: Top 10 Companies in Immunology

Figure 10: Top 20 Drugs in Immunology

Figure 11: Proportion of Total Drug Sales Across All JAK Inhibitors

Figure 12: Total Sales for Interleukin Inhibitors in Immunology

Figure 13: Projected Total Sales of Biosimilars Approved as of 2017

Figure 14: Top 10 Companies in Neurology

Figure 15: Top 20 Drugs in Neurology

Figure 16: Key Developments in the 5-HT6 Receptor Antagonist Class in Alzheimer’s Disease in 2017

Figure 17: Projected Total Sales of Injectable Based Therapies for MS

Figure 18: Top 10 Companies in Cardiovascular Diseases

Figure 19: Top 20 Drugs in Cardiovascular Diseases

Figure 20: Top 10 Companies in Metabolic Disorders

Figure 21: Top 20 Drugs in Metabolic Disorders

Figure 22: Historical Global Sales of PCSK9 Inhibitors ($M)

Figure 23: 2017 PCSK9 Inhibitor Global Market Share

Figure 24: 2022 PCSK9 Inhibitor Global Market Share

Figure 25: GLP-1 Receptor Agonist and SGLT-2 Inhibitor Influx for Type 2 Diabetes Continues

Figure 26: Historical and Projected Global Sales of Branded NOACs, Direct Factor Xa Inhibitors ($M)

Figure 27: Top 10 Companies in ID

Figure 28: Top 20 Products in ID

Figure 29: Projected Sales of Heplisav-B ($M)

Figure 30: Projected Market Shares for Herpes Zoster (Shingles) Vaccines Approved as of 2017

Figure 31: Projected Sales of Vabomere vs. Similar Antibiotics

Figure 32: Top 10 Companies in Ophthalmology

Figure 33: Top 20 Drugs in Ophthalmology

Figure 34: Historical Sales of Lucentis and Eylea ($B)

Figure 35: GlobalData’s Forecast Share of Key Ophthalmology Markets in 2016

Figure 36: Projected Total Sales of Biosimilars in Key Ophthalmology Markets

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Join our mailing list

Saved reports